Doug Brunk is a San Diego-based award-winning reporter who began covering health care in 1991. Before joining the company, he wrote for the health sciences division of Columbia University and was an associate editor at Contemporary Long Term Care magazine when it won a Jesse H. Neal Award. His work has been syndicated by the Los Angeles Times and he is the author of two books related to the University of Kentucky Wildcats men's basketball program. Doug has a master’s degree in magazine journalism from the S.I. Newhouse School of Public Communications at Syracuse University. Follow him on Twitter @dougbrunk.
News
Phase 2 studies of novel JAK1 inhibitor for HS show promise
Specifically targeting JAK1 may reduce cytokine signaling involved in HS pathogenesis while limiting JAK2-mediated cytopenias.
News
FDA approves two JAK-1 inhibitors for moderate to severe atopic dermatitis
“It’s big news because a few years ago we didn’t have any systemic treatments that are safer than the classical immunosuppressants.”
News
Hand eczema and atopic dermatitis closely linked
“As clinicians, we sometimes need to rule out a few differentials, including psoriasis and T-cell lymphoma,” Dr. Jacob P. Thyssen said.
News
Sorting out sleep complaints in children with AD can be complex
“There’s a loss of about 50 minutes of sleep per night in children with AD,” Dr. Stephen H. Sheldon said.
News
Key questions to ask atopic dermatitis patients with sleep complaints
Assessment tools to consider are the Epworth Sleepiness Scale, the Insomnia Severity Index, and the STOP-Bang questionnaire.
News
Longitudinal course of atopic dermatitis often overlooked, expert says
“Understanding the long-term course may improve our ability to phenotype, prognosticate, and personalize our care,” Dr. Raj Chovatiya said.
News
Itch-dominant atopic dermatitis often flies under the radar
A disconnect often exists between clinician-reported and patient-reported outcome measures, says Dr. Jonathan Silverberg.
News
Atopic dermatitis can be especially burdensome in the elderly
There is good data on higher relative risk of osteoporosis/fractures and dementia specifically among older adults with AD.
News
FDA gives nod to tralokinumab for adults with moderate to severe AD
The drug is expected to be available by February 2022.
News
AD burden may be greater for those with head, neck, face, and hand involvement
“These findings highlight the importance of detailed assessment of specific areas affected by AD to personalize treatment approaches to the needs...
News
Is it safe to pair low-power fractional diode lasers with cosmetic injectables in a single session?
“Additional prospective studies are still needed to further validate our findings,” Dr. Jordan V. Wang said.
News
Dermatologists driving use of vascular lasers in the Medicare population
Reimbursement rates were greatest in the Western geographic region of the United States.